268 related articles for article (PubMed ID: 12193305)
1. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy.
Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
Thyroid; 2002 Jul; 12(7):603-8. PubMed ID: 12193305
[TBL] [Abstract][Full Text] [Related]
2. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment.
Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
Thyroid; 2005 Apr; 15(4):358-63. PubMed ID: 15876160
[TBL] [Abstract][Full Text] [Related]
3. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
4. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy.
Gerding MN; van der Zant FM; van Royen EA; Koornneef L; Krenning EP; Wiersinga WM; Prummel MF
Clin Endocrinol (Oxf); 1999 Mar; 50(3):373-9. PubMed ID: 10435064
[TBL] [Abstract][Full Text] [Related]
5. [Octreotide scintigraphy for the diagnosis of active Graves' ophthalmopathy].
Ardjomand N; Esche G; Fellner P; Lindner S; Panzitt M; Aigner R; Langmann A
Ophthalmologe; 2003 Dec; 100(12):1049-53. PubMed ID: 14704818
[TBL] [Abstract][Full Text] [Related]
6. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy.
Ohtsuka K; Sato A; Kawaguchi S; Hashimoto M; Suzuki Y
Am J Ophthalmol; 2003 Mar; 135(3):285-90. PubMed ID: 12614743
[TBL] [Abstract][Full Text] [Related]
7. Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy.
Ujhelyi B; Erdei A; Galuska L; Varga J; Szabados L; Balazs E; Bodor M; Cseke B; Karanyi Z; Leovey A; Mezosi E; Burman KD; Berta A; Nagy EV
Thyroid; 2009 Apr; 19(4):375-80. PubMed ID: 19355827
[TBL] [Abstract][Full Text] [Related]
8. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.
Kahaly G; Diaz M; Hahn K; Beyer J; Bockisch A
J Nucl Med; 1995 Apr; 36(4):550-4. PubMed ID: 7699440
[TBL] [Abstract][Full Text] [Related]
9. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves' disease.
Burggasser G; Hurtl I; Hauff W; Lukas J; Greifeneder M; Heydari B; Thaler A; Wedrich A; Virgolini I
J Nucl Med; 2003 Oct; 44(10):1547-55. PubMed ID: 14530465
[TBL] [Abstract][Full Text] [Related]
10. Tc-99m polyclonal human immunoglobulin G imaging in Graves' ophthalmopathy.
Durak H; Söylev M; Durak I; Değirmenci B; Capa Kaya G; Uysal B
Clin Nucl Med; 2000 Sep; 25(9):704-7. PubMed ID: 10983759
[TBL] [Abstract][Full Text] [Related]
11. (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO).
Sun H; Jiang XF; Wang S; Chen HY; Sun J; Li PY; Ning G; Zhao YJ
Endocrine; 2007 Jun; 31(3):305-10. PubMed ID: 17906380
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin-receptor scintigraphy in Graves' disease: reproducibility and variance of orbital activity.
Förster GJ; Krummenauer F; Nickel O; Kahaly GJ
Cancer Biother Radiopharm; 2000 Oct; 15(5):517-25. PubMed ID: 11155823
[TBL] [Abstract][Full Text] [Related]
13. [Clinical application of orbital scintigraphy with 99Tc(m)-octreotide in patients with thyroid associated ophthalmopathy].
Duan L; Li XF; Lu KY; Zhang CG; Hu G; Liu JZ; Li SJ
Zhonghua Yan Ke Za Zhi; 2006 Dec; 42(12):1068-72. PubMed ID: 17415962
[TBL] [Abstract][Full Text] [Related]
14. Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters.
Gerding MN; Prummel MF; Wiersinga WM
Clin Endocrinol (Oxf); 2000 May; 52(5):641-6. PubMed ID: 10792345
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
16. A pilot study evaluating 99mTc-anti-TNF-alpha scintigraphy in graves' ophtalmopathy patients with different clinical activity score.
Rebelo Pinto Edos S; Lopes FP; de Souza SA; da Fonseca LM; Vaisman M; Gutfilen B; dos Santos Teixeira Pde F
Horm Metab Res; 2013 Sep; 45(10):765-8. PubMed ID: 23918686
[TBL] [Abstract][Full Text] [Related]
17. Indium-111-pentetreotide in Graves' disease.
Kahaly G; Görges R; Diaz M; Hommel G; Bockisch A
J Nucl Med; 1998 Mar; 39(3):533-6. PubMed ID: 9529305
[TBL] [Abstract][Full Text] [Related]
18. 99mTc(V)-DMSA SPECT for the assessment of disease activity in Graves' ophthalmopathy.
Reyhan M; Toygar O; Sukan A; Seydaoglu G; Bakiner OS; Aydin M; Yapar AF; Aktas A
Nucl Med Commun; 2007 Oct; 28(10):775-81. PubMed ID: 17728607
[TBL] [Abstract][Full Text] [Related]
19. Relationships of orbital computed tomographic findings and activity scores to the prognosis of corticosteroid therapy in patients with Graves' ophthalmopathy.
Chang TC; Huang KM; Hsiao YL; Tzeng SS; Kao SC
Acta Ophthalmol Scand; 1997 Jun; 75(3):301-4. PubMed ID: 9253980
[TBL] [Abstract][Full Text] [Related]
20. 111In-octreotide in the evaluation of autoimmune thyroid diseases.
Mansi L; Rambaldi PF; Bizzarro A; Panza N; Del Vecchio E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):127-30. PubMed ID: 9002770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
